Amgen (NASDAQ:AMGN) Price Target Raised to $415.00

Amgen (NASDAQ:AMGN) had its target price lifted by The Goldman Sachs Group from $403.00 to $415.00 in a research note published on Wednesday morning,MarketScreener reports. The Goldman Sachs Group currently has a buy rating on the medical research company’s stock.

AMGN has been the subject of a number of other reports. Argus boosted their price target on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a research note on Tuesday, December 30th. Wells Fargo & Company upped their target price on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Daiwa Securities Group increased their price target on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. Citigroup lifted their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Truist Financial increased their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $351.65.

Amgen Trading Up 4.5%

AMGN stock opened at $384.20 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen has a twelve month low of $261.43 and a twelve month high of $385.12. The company has a market cap of $206.88 billion, a P/E ratio of 27.00, a PEG ratio of 3.73 and a beta of 0.46. The business has a fifty day moving average of $334.45 and a 200-day moving average of $311.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the company earned $5.31 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts expect that Amgen will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.6%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is presently 66.90%.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 10,908 shares of company stock worth $3,674,966 over the last ninety days. 0.76% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amgen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. High Note Wealth LLC increased its holdings in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after purchasing an additional 28 shares in the last quarter. West Family Investments Inc. boosted its position in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares during the period. Viawealth LLC boosted its position in shares of Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after buying an additional 30 shares during the period. LOM Asset Management Ltd grew its holdings in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after buying an additional 30 shares in the last quarter. Finally, Smith Salley Wealth Management raised its position in Amgen by 0.3% in the 4th quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after buying an additional 30 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.